Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 4/20 | 0.66 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 3/20 | 0.51 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443167 | 0.91 | NSD2 (0.55) | NSD2USP30ALDH1A1KDM4EMEN1 | |
| SCHEMBL4453000 | 0.90 | NSD2 (0.53) | NSD2USP30ALDH1A1CCR8FABP4 | |
| SCHEMBL4453211 | 0.89 | NSD2 (0.52) | NSD2ALDH1A1CCR8FABP4GAA | |
| SCHEMBL4443344 | 0.87 | LMNA (0.55) | NSD2USP30CCR8LMNACNR1 | |
| SCHEMBL4455045 | 0.86 | CCR8 (0.54) | NSD2CCR8FABP4LMNA | |
| SCHEMBL4449304 | 0.86 | CCR8 (0.53) | NSD2USP30ALDH1A1KDM4EMEN1 | |
| SCHEMBL4446944 | 0.86 | NSD2 (0.64) | NSD2USP30ALDH1A1KDM4ECCR8 | |
| SCHEMBL4448416 | 0.86 | NSD2 (0.54) | NSD2CCR8EDNRA | |
| SCHEMBL4444970 | 0.86 | FABP4 (0.56) | NSD2ALDH1A1CCR8FABP4LMNA | |
| SCHEMBL4453218 | 0.85 | CCR8 (0.55) | NSD2CCR8EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547716-B2 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1402890-B1 | SULFONAMIDE DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1402890-A1 | SULFONAMIDE DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | NSD2 122/4885USP30 4114/4885ALDH1A1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.